Blog

The views and opinions expressed herein are those of the author and do not necessarily reflect those of BehaveNet, Inc.

12/18/2014

Before I finished the question I knew the answer: The Bunavail rep, citing FDA restrictions, could not tell me that patients can cut the new buprenorphine/naloxone product to reduce the dose.

Never mind that the company, Biodelivery, undoubtedly has already spent millions to develop this new Suboxone competitor and obtain approval. Never mind that patients will cut the product in half regardless of whether anyone, even the FDA, tells them it’s OK.

We will all praise the Emperor’s beautiful new clothes.

I cannot yet report the result of any patient taking this enormous risk. I can only observe that this new product seems less brittle than Suboxone, so it seems unlikely to break when bent.

Regardless, let us hope competition will bring the prices of all the branded combination drugs down closer to that of generic buprenorphine.

Add a comment
QR code

Opinion

Daily Tweets

CNS Drug: #CNSDOD
Notable Person: #BHCPOD
Phobia: #BNphobia
Term: #BHCTOD

National Conference Tweetchats

1/14-18: APsaA
#APsaAMeeting2015

Glossaries

Connect with us